Unlocking the possibilities of BCMA-directed therapies in RRMM: Latest perspectives from IMS and ASH 2025

touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY Listen to multiple myeloma expert Dr Rakesh Popat review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the International Multiple Society (IMS) and American Society of Hematology (ASH) 2025 congresses. Dr Popat is then joined by fellow experts Dr Paula Rodríguez-Otero and Dr Roberto Mina to discuss the implications of these data for current and future clinical practice.   Overview Data reviews with Dr Popat Expert panel discussions with Dr Popat, Dr Rodríguez-Otero and Dr Mina on the themes below Clinical themes Approved BCMA-directed therapeutic approaches  Practical application of BCMA-directed therapies Future of treating RRMM: Emerging BCMA-directed therapies and combinations The internationally renowned multiple myeloma expert faculty Dr Rakesh Popat: London, UK Dr Paula Rodríguez-Otero: Pamplona, Spain Dr Roberto Mina: Atlanta, GA, USA This touchPODCAST is for HCPs outside of the USA.  This activity is funded by an independent medical education grant from GSK. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com